MedTrace Logo

Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

NCT00878969 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2016-02-15

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to see how two classes of blood pressure medications,angiotensin-converting enzyme inhibitors (Ace inhibitors) and angiotensin receptor blockers (ARBs), differ in their long term effects on certain chemicals in the body and on the carotid arteries.

Conditions

  • Oxidative Stress
  • Endothelial Dysfunction

Interventions

DRUG

valsartan (ARB)

DRUG

ramipril (ACE inhibitor)

DRUG

Placebo

Sponsors & Collaborators

  • University of Washington

    collaborator OTHER

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Nancy J Brown, MD · Vanderbilt University Medical Center

  • Talat A Ikilzer, MD · Vanderbilt University Medical Center

  • Jonathan Himmelfarb, MD · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00878969 on ClinicalTrials.gov